Sage Therapeutics, Inc. SAGE and partner Biogen Inc. BIIB announced that they plan to submit a new drug application (“NDA”) for their oral depression candidate, zuranolone, in the second half of 2022.
(RTTNews) - Sage Therapeutics, Inc. (SAGE), a biopharmaceutical company , and Biogen Inc. (BIIB), a biotechnology firm, on Tuesday said they plan to submit a New Drug Application or NDA to the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results